Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Cell Therapeutics Rises on Study Drug Agreement

By Pharmaceutical Processing | October 8, 2013

NEW YORK (AP) — Shares of Cell Therapeutics rose Monday after the company said it had reached an agreement with regulators about the design of a key trial of an experimental drug.

The agreement covers the design and goals of a late-stage trial of pacritinib as a treatment for myelofibrosis, a blood disorder. Cell Therapeutics said it will enroll 300 patients in the 24-week trial. The study will compare pacritinib to the best available treatment, including Jakafi, a myelofibrosis drug that was approved in 2011. The study will measure the number of patients who experience at least a 35-percent reduction in spleen volume and the percentage of patients whose symptoms are reduced by at least 50 percent.

The agreement makes it more likely the FDA will approve pacritinib if it meets its goals in the trial.

Myelofibrosis causes anemia, fatigue, pain and swelling of the spleen. It causes abnormal blood cells to build up in bone marrow, forming thick scar tissue that slows the production of healthy blood cells. To make up for the shortage, other organs including the liver and the spleen begin producing blood cells.

The Seattle company is already running one late-stage trial of pacritinib.

Shares of Cell Therapeutics advanced 15 cents, or 9.4 percent, to $1.74 in midday trading.

Cell Therapeutics Inc. has one approved drug, the lymphoma drug Pixuvri. Revenue from Pixuvri totaled $300,000 in the second quarter. The company is also studying a drug called Opaxio as a treatment for glioblastoma, the most common type of brain cancer.

Jakafi is marketed by Incyte Corp. and Novartis AG. Shares of Incyte lost $1.21, or 3 percent, to $38.90.

Related Articles Read More >

GSK
GSK invests another $800M in Pennsylvania site expansions
This is a BD image of its major IV catheters manufacturing facility in Sandy, Utah, which the company said produces billions of molded components each year.
BD to invest billions in U.S. manufacturing
Diverse factory workers in yellow PPE suits checking production data with clipboard in modern industrial facility, Quality control inspector wearing masks and hairnets working in food or pharma plant
ISO 9001, 14001 and 45001 revisions: What changes and when to start
Artis BioSolutions announces new center of excellence in Spain
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE